nach oben

Erschienen in:

01.11.2010 | Rapid communication

Seroprevalence of human T-cell lymphotropic virus type 1 and 2 in blood donors from the regional hospital of Valdivia, Chile

verfasst von: Luis Chandía, Cristina Sotomayor, Sylvia Ordenes, Pilar Salas, Maritza Navarrete, Mauricio Lopez, Carola Otth

Erschienen in: Medical Microbiology and Immunology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

It is estimated that 15–20 millions of people are infected with human T-cell lymphotropic virus 1/2 (HTLV-1/2) worldwide, and 20–30% of them are Latin Americans. The seroprevalence rates vary according to geographic area, socio-demographic composition and individual risk behaviors. The impact of HTLV-1-associated diseases on the community, as well as the increasing concerns about blood transfusion safety due to infectious transmitted agents, has required mandatory screening assays of blood donors as an effective preventive strategy in HTLV-1 transmission. The aim of this study was to estimate the seroprevalence of HTLV-1/2 in blood donors from Valdivia, southern Chile during the first year of mandatory screening of HTLV by Chilean government. Blood samples were collected from blood donors between May 2009 and 2010 at the Regional Hospital of Valdivia, Chile. Serum samples were screened for antibodies against HTLV-1/2 by enzyme-linked immunosorbent assay MUREX HTLV I + II Abbott. Among 6,237 samples tested by serological assay, 28 samples were reactive; nevertheless, confirmatory techniques indicate that only 15 samples were positive to HTLV-1. Our study shows HTLV-1 seroprevalence of 0.24%, indicating a similar seroprevalence associated with blood donors than previous reports for our country.

Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058–6068CrossRefPubMed

Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415–7419CrossRefPubMed

Yoshida M, Miyoshi I, Hinuma Y (1982) Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79:2031–2035CrossRefPubMed

Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A et al (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031–1032CrossRefPubMed

Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B (2003) Human T cell leukemia virus ype I-induced disease: pathways to cancer and neurodegeneration. Virology 308:1–12CrossRefPubMed

Edlich RF, Arnette JA, Williams FM (2000) Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 18:109–119CrossRefPubMed

Galvao-Castro B, Loures L, Rodriques LG, Sereno A, Ferreira OC Jr, Franco LG et al (1997) Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study. Transfusion 37:242–243CrossRefPubMed

Kazanji M, Gessain A (2003) Human T-cell lymphotropic virus types I and II (HTLV-I/II) in French Guiana: clinical and molecular epidemiology. Cad Saude Pub 19:1227–1240

Leon G, Quiros AM, Lopez JL, Hung M, Diaz AM, Goncalves J et al (2003) Seropositivity for human T-lymphotropic virus types I and II among donors at the municipal blood bank of caracas and associated risk factors. Rev Panam Salud Pub 13:117–123

10.

Sanchez-Palacios C, Gotuzzo E, Vandamme AM, Maldonado Y (2003) Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse peruvian women. Int J Infect Dis 7:132–137CrossRefPubMed

11.

Gastaldello R, Hall WW, Gallego S (2004) Seroepidemiology of HTLV-I/II in Argentina: an overview. J Acq Immun Def Synd 35:301–308CrossRef

12.

Zaninovic V, Sanson F, Lopez F, Velandia G, Blank A, Blank M et al (1993) Geographic independence of HTLV-I and HTLV-II foci in the andes highland, the Atlantic coast, and the orinoco of Colombia. AIDS Res Hum Retrovir 10:97–101CrossRef

13.

Cartier L, Tajima K, Araya F, Castillo JL, Zaninovic V, Hayami M et al (1993) Preliminary report on the prevalence of serum antibodies against HTLV-I in Chilean aboriginal populations. Rev Med Chile 121:242–246

14.

Inostroza J, Diaz P, Saunier C (1991) Prevalence of antibodies to HTLV-1 in south American Indians (Mapuches) from Chile. Scand J Infect Dis 23:507–508CrossRefPubMed

15.

Vasquez P, Sánchez G, Volante C, Vera L, Ramírez E, Soto G et al (1991) Human T-Lymphotropic virus type I: new risk for Chilean population. Blood 78:850–851PubMed

16.

Vasquez P (2003) HTLV-I (Human T–cell lymphotropic virus), algo que decir? Rev Chil Infect 20(Supl 1):S34–S37

17.

Cartier L, Cartier E (1996) HTLV-I-II in Chile. In: Zaninovic V (ed) HTLV, truths and questions. Fund. Mar, Cali, pp 150–158

18.

Cartier L, Mora C, Araya J, Castillo J, Verdugo R, Miller MA et al (1989) HTLV-I positive spastic paraparesis in a temperate zone. Lancet 1:556–557

19.

Galeno H, Ramirez E, Mora J, Ojeda M, Cartier L (1994) Anti HTLV-I antibody titers in seropositive infected individuals. Rev Med Chile 122:1004–1007PubMed

20.

Cartier L, Araya F, Castillo JL, Verdugo R, Mora C, Gajdusek DC, Gibbs C (1990) HTLV-I provirus in Chile, study of 140 neurological patients. Rev Med Chile 118:622–628PubMed

21.

Galeno H, Ramirez E, Cartier L (1996) HTLV-I provirus in seronegative chilean patients with tropical spastic paraparesis. Lancet 348:1170CrossRefPubMed

22.

Ramirez E, Cartier L, Flores R (2004) In vitro cytoskeleton changes of mouse neurons induced by purified HTLV-I, and PBMC from HAM/TSP patients and HTLV-I carriers. Arch Virol 149:2307–2317CrossRefPubMed

23.

Ramirez E, Cartier L, Torres M, Barria M (2007) Temporal dynamics of human T-lymphotropic virus type I tax mRNA and proviral DNA load in peripheral blood mononuclear cells of human T-lymphotropic virus type I-associated myelopathy patients. J Med Virol 79:782–790CrossRefPubMed

24.

Li HC, Fujiyoshi T, Lou H, Yashiki S, Sonoda S, Cartier L et al (1999) The presence of ancient human T-cell lymphotropic virus type I provirus DNA in an andean mummy. Nat Med 5:1428–1432CrossRefPubMed

25.

Cartier L, Araya F, Castillo JL, Zaninovic V, Hayami M, Miura T et al (1993) Southern-most carriers of HTLV-I/II in the world. Jpn J Cancer Res 84:1–3PubMed

26.

Uchiyama T (1997) Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 15:15–37CrossRefPubMed

27.

Manns A, Wilks RJ, Murphy EL, Haynes G, Figueroa JP, Barnett M et al (1992) A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 51:886–891CrossRefPubMed

28.

Berini CA, Susana Pascuccio M, Bautista CT, Gendler SA, Eirin ME, Rodriguez C, Pando MA, Biglione MM (2008) Comparison of four commercial screening assays for the diagnosis of human T-cell lymphotropic virus types 1 and 2. J Virol Methods 147:322–327CrossRefPubMed

Titel: Seroprevalence of human T-cell lymphotropic virus type 1 and 2 in blood donors from the regional hospital of Valdivia, Chile
verfasst von: Luis Chandía
Cristina Sotomayor
Sylvia Ordenes
Pilar Salas
Maritza Navarrete
Mauricio Lopez
Carola Otth
Publikationsdatum: 01.11.2010
Verlag: Springer-Verlag
Erschienen in: Medical Microbiology and Immunology / Ausgabe 4/2010
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-010-0166-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Seroprevalence of human T-cell lymphotropic virus type 1 and 2 in blood donors from the regional hospital of Valdivia, Chile

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Human immunodeficiency virus type-1 group M quasispecies evolution: diversity and divergence in patients co-infected with active tuberculosis

Pro-autophagic signal induction by bacterial pore-forming toxins

Chlamydia pneumoniae infection and Alzheimer’s disease: a connection to remember?

Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient

PI3K-dependent host cell actin rearrangements are required for Cronobacter sakazakii invasion of human brain microvascular endothelial cells

Rapid quantitation of cytomegalovirus DNA in whole blood by a new molecular assay based on automated sample preparation and real-time PCR

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin